Additionally, FGFR inhibitors, particularly PD173074, a well-known FGFR inhibitor, have also been shown to reverse the EMT phenotype of head and neck squamous cell carcinoma (HNSCC) cells and induce a mesenchymal-to-epithelial transition (MET) via the transcription factor AP-1, thereby suppressing cancer cell growth and invasion [173]. This evidence concerns the gene JUN and head and neck squamous cell carcinoma.